Burosumab

證據等級: L5

預測適應症: 0 個

BUROSUMAB: Repurposing Candidate — No TxGNN Predictions Available

One-Sentence Summary

BUROSUMAB (DrugBank ID: DB14012) is a biological drug with no TFDA marketing authorization records in Taiwan. The current Evidence Pack contains no TxGNN-predicted indications, making a formal repurposing evaluation impossible at this stage. Two blocking data gaps — mechanism of action and package insert safety data — must be resolved before this candidate can advance.

Quick Overview

Item	Content
Original Indication	Not available (no TFDA authorization records)
Predicted New Indication	None generated
TxGNN Prediction Score	N/A
Evidence Level	N/A
Taiwan Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available, and the TxGNN pipeline generated no predicted indications for this candidate. Without a target indication, mechanistic plausibility analysis cannot be conducted. The sections below document the two blocking gaps preventing this evaluation from moving forward.

Gap 1 — Mechanism of Action (MOA) · Severity: High Without MOA data, it is not possible to assess whether BUROSUMAB's pharmacological activity is relevant to any candidate new indication. Remediation: query DrugBank API for DB14012 and extract the mechanism of action field.

Gap 2 — Package Insert Safety Data · Severity: Blocking Without TFDA-sourced warnings and contraindications, the candidate cannot pass initial safety screening, which is a prerequisite for all downstream evaluation steps. Remediation: download and parse the TFDA package insert PDF for BUROSUMAB.

Clinical Trial Evidence

Currently no related clinical trials registered — no predicted indication available to search against.

Literature Evidence

Currently no related literature available — no predicted indication available to search against.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for BUROSUMAB is structurally incomplete: the TxGNN pipeline produced no predicted indications, and two data gaps classified as Blocking and High severity prevent the evaluation from proceeding at any stage.

To proceed, the following is needed:

Re-run the TxGNN prediction pipeline for BUROSUMAB (DB14012) to generate candidate disease indications
Retrieve mechanism of action data via the DrugBank API (DB14012)
Download and parse the TFDA package insert PDF to extract warnings, contraindications, and dosing safety information
Conduct drug-drug interaction screening once basic safety data is confirmed
Re-issue the Evidence Pack and re-trigger report generation after the above gaps are resolved
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.